Proteon Therapeutics Announces Top-Line Data from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with CKD
December 13, 2016 07:00 ET
|
Proteon Therapeutics, Inc.
- Trial Did Not Meet Primary Efficacy Endpoint - - Important Secondary and Tertiary Endpoint Data and Enrollment in Second Phase 3 Ongoing - - Conference Call Scheduled for 8:30 AM ET - WALTHAM,...
Proteon Therapeutics to Participate in Two Upcoming Investor Conferences
November 09, 2016 16:35 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Third Quarter 2016 Financial Results
November 07, 2016 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Appoints Paul Hastings Chairman of Its Board of Directors
October 20, 2016 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics to Present at Two Upcoming Investor Conferences
September 01, 2016 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Second Quarter 2016 Financial Results
August 08, 2016 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 22nd
June 15, 2016 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., June 15, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients...
Proteon Therapeutics Announces First Quarter 2016 Financial Results
May 09, 2016 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., May 09, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Survey Findings Demonstrating Impact of Vascular Access Failure on Hemodialysis Patients
April 28, 2016 07:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., April 28, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
U.S. FDA Approves Rockwell’s Triferic® Powder Packet for Treating Anemia in Hemodialysis Patients
April 26, 2016 08:00 ET
|
Rockwell Medical, Inc.
WIXOM, Mich., April 26, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney...